MicroRNA encapsulated nanocells - EnGeneIC

Drug Profile

MicroRNA encapsulated nanocells - EnGeneIC

Alternative Names: EGFREDVmiR-16; MicroRNA packaged EDVTM nanocells - EnGeneIC; TargomiR; TargomiRs - EnGeneIC

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EnGeneIC
  • Developer Asbestos Diseases Research Institute; EnGeneIC; University of Sydney
  • Class Antineoplastics; Cell therapies; MicroRNAs
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mesothelioma

Most Recent Events

  • 05 Sep 2017 Updated efficacy and adverse events data from the phase I/IIa MesomiR 1 trial in Mesothelioma released by EnGeneIC
  • 27 Mar 2017 Phase-I/II development for Mesothelioma (Late-stage disease, Second-line therapy or greater) is ongoing in Australia (IV)
  • 01 Jan 2017 EnGeneIC completes a phase I/II trial for Mesothelioma (Late-stage disease, Second-line therapy or greater) in Australia (IV) (NCT02369198)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top